Gary M. Nath (DC, NI) Harold L. Novick (DC, MD) Todd L. Juneau (DC, IL) Ross A. Epstein (CA)*

Irvin A. Lavine (DC), Retired

Bonald M. Sandler (MD), Retired*

Patent, Trademark and Copyright Causes Unfair Competition, Trade Secrets, Licensing and Litigation

*Practice limited to Matters and Proceedings before Federal Courts and Agencies; not Admitted in DC NATH & ASSOCIATES PLLC

Attorneys at Law 1030 Fifteenth Street, N.W. Sixth Floor Washington, D.C. 20005-1503

> TELEPHONE (202) 775-8383 (202) 775-9393 FACSIMILE (202) 775-8396 (202) 822-9409 E-MAIL: IP@NATHLAW.COM

WEB: WWW.NATHLAW.COM

Michelle L. Hardandy

Lee C. Haiman C.

Jerald L. Meyer (M)

Marvin C. Berkovilk (Gh)

Tanya E. Hardik (M)

Joshua B. Goldberg (M)

Todd W. Kunz (U)

Sheldon M. McGer (PC)

Alvin E. Tane Holtz

** Registered Patent Agent: not Administra n DC ++ Limited Rep. at USPTO

François A. Pelaez PhD



REQUEST FOR

CONTINUED EXAMINATION (RCE)

TRANSMITTAL

Commissioner of Patents Box RCE Washington, D.C. 20231

Application No Filing Date:

Title:

09/537,088

March 29, 2000

DWIVEDI et al.

NOVEL INCLUSION COMPLEXES OF A HIGH POTENT

OPIOID PEPTIDE, PHARMACEUTICAL

COMPOSITIONS AND METHOD OF TREATMENT

Inventors:

Group Art Unit:

Examiner:

1653

Atty Docket No:

J. Russel 82239

Sir:

This is a Request for Continued Examination (RCE) under 37 C.F.R \S 1.114 of the above-identified application.

Note: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the aboveidentified application was filed prior to May 29, 2000, applicant may
wish to consider filing a continued prosecution application (CPA)
under 37 C.F.R. § 1.53(d) (PTO/SB/29) instead of a RCE to be eligible
for the patent term adjustment provisions of the AIPA. See Changes
to Application Examination and Provisional Application and
Provisional Application Practice, Final Rule 65 Fed.Reg. 50092 9Aug.
16, 2000); Interim Rule, 65 Fed. Reg. 14865 (mar. 20, 2000), 1233
Off.Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE
pratice.

05/06/2002 AWONDAF1 00000107 09537088

01 FC:179

740.00 QP

Atty. Docket No.: 82239 Page 2 of 2

1. Submission required under 37 C.F.F. § 1.114
a. X Previously submitted i. X Consider the amendments(s)/reply under 37 C.F.R.§ 1.116 previously filed on 5/2/02— ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on Other
c Enclosed iAmendment/Reply iiAffidavit(s)/Declaration(s) iiiInformation Disclsoure Statement(IDS) ivOther
2. Miscellaneaous
aSuspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of months.(Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required) bOther
3. Fees (The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed)
a. \underline{X} The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Acct. No. $\underline{14-0112}$.
i. X RCE fee of \$ 740.00 required under 37 C.F.R. § 1.17 (e) is enclosed. ii. Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) iii. Other
Respectfully submitted, NATH & ASSOCIATES PLLC
Harold L. Novick Registration No. 26,011 Customer No. 20529
Date: 5/3/07— NATH & ASSOCIATES PLLC 1030 15 TH Street NW - 6 th Floor Washington, D.C. 20005 HLN/JBG(RCE)

MAY 0 3 7007 CC

#10

BOX PATENT

Attorney Docket No.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Group Art Unit: 1653

DWIVEDI et al./

Examiner: J. RUSSEL

Serial No. 09/537,088

Filed: March 29, 2000

For: NOVEL INCLUSION COMPLEXES OF A HIGH POTENT OPIOID PEPTIDE, PHARMACEUTICAL COMPOSITIONS AND METHOD OF TREATMENT

RESPONSE TO OFFICIAL ACTION

Commissioner for Patents Washington, D.C. 20231

Sir:

This is in response to the Final Office Action having a mailing date of November 7, 2001, with the three month shortened statutory period to respond set to expire on February 7, 2002. A petition for a three-month extension of time and a check are filed herewith extending the period for response to May 7, 2002. Accordingly, this Response is timely filed.

In view of the following remarks, applicants respectfully request the Examiner to reconsider and withdraw the outstanding rejections and allow all claims pending in this application.

AMENDMENT

IN THE SPECIFICATION

Please amend the specification as indicated in Appendices A